Human Resources Committee – Week 5, 2020


SF 2119– Controlled Substance Schedules

SF 2119 relates to controlled substances. It allows the Pharmacy Board to change the schedule status of cannabis-derived products and cannabis-derived investigational products based on decisions of the Food and Drug Administration and the Federal Drug Enforcement Administration. The bill classifies nine synthetic opioids, one opioid analgesic, 10 synthetic cannabinoids and seven synthetic cathinones as Schedule I substances, meaning they have no known medical use. It classifies all products containing derivatives of barbituric acid as Schedule II. It classifies one central nervous system depressant and one central nervous system stimulant as Schedule IV, and any FDA-approved product containing cannabidiol with no more than 0.1 percent THC as Schedule V. The bill also strikes language regarding medical marijuana programs at the Board of Pharmacy. 
[2/10: 48-0 (Excused: Nunn, T. Taylor)]

SF 2120– Prescription Monitoring Program

SF 2120 allows veterinarians to register for and access information from the state’s Prescription Monitoring Program. Some veterinarians can prescribe controlled substances, and there have been instances of pet owners taking the animal’s medication. The bill also expands PMP reporting requirements to all Schedule III and IV controlled substances and to all Schedule V controlled substances except pseudoephedrine. Additional substances that the PMP Advisory Council and Board of Pharmacy determine could be addictive or fatal are also included in the required PMP reporting. The due date for the PMP annual reports is changed to February 1 instead of January 1.
[2/10: 48-0 (Excused: Nunn, T. Taylor)]